| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ... The American Journal of Human Genetics 72 (5), 1117-1130, 2003 | 4904 | 2003 |
| Gene-expression profiles in hereditary breast cancer I Hedenfalk, D Duggan, Y Chen, M Radmacher, M Bittner, R Simon, ... New England Journal of Medicine 344 (8), 539-548, 2001 | 2175 | 2001 |
| Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor–positive breast cancer SN Stacey, A Manolescu, P Sulem, T Rafnar, J Gudmundsson, ... Nature genetics 39 (7), 865-869, 2007 | 898 | 2007 |
| Parental origin of sequence variants associated with complex diseases A Kong, V Steinthorsdottir, G Masson, G Thorleifsson, P Sulem, ... Nature 462 (7275), 868-874, 2009 | 669 | 2009 |
| The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions AC Antoniou, AP Cunningham, J Peto, DG Evans, F Lalloo, SA Narod, ... British journal of cancer 98 (8), 1457-1466, 2008 | 645 | 2008 |
| Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer SN Stacey, A Manolescu, P Sulem, S Thorlacius, SA Gudjonsson, ... Nature genetics 40 (6), 703-706, 2008 | 549 | 2008 |
| Distinct Somatic Genetic Changes Associated with Tumor Progression in Carriers of BRCA1 and BRCA2 Germ-line Mutations M Tirkkonen, O Johannsson, BA Agnarsson, H Olsson, S Ingvarsson, ... Cancer research 57 (7), 1222-1227, 1997 | 485 | 1997 |
| High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families A Borg, T Sandberg, K Nilsson, O Johannsson, M Klinker, A Måsbäck, ... Journal of the National Cancer Institute 92 (15), 1260-1266, 2000 | 439 | 2000 |
| Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer MM Tanner, S Grenman, A Koul, O Johannsson, P Meltzer, T Pejovic, ... Clinical Cancer Research 6 (5), 1833-1839, 2000 | 437 | 2000 |
| Tumour biological features of BRCA1-induced breast and ovarian cancer OT Johannsson, I Idvall, C Anderson, Ĺ Borg, RB Barkardottir, V Egilsson, ... European journal of cancer 33 (3), 362-371, 1997 | 431 | 1997 |
| Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer N Loman, O Johannsson, U Kristoffersson, H Olsson, A Borg Journal of the National Cancer Institute 93 (16), 1215-1223, 2001 | 364 | 2001 |
| A germline variant in the TP53 polyadenylation signal confers cancer susceptibility SN Stacey, P Sulem, A Jonasdottir, G Masson, J Gudmundsson, ... Nature genetics 43 (11), 1098-1103, 2011 | 330 | 2011 |
| Survival of BRCA1 breast and ovarian cancer patients: a population-based study from southern Sweden. OT Johannsson, J Ranstam, A Borg, H Olsson Journal of Clinical Oncology 16 (2), 397-404, 1998 | 324 | 1998 |
| High prevalence of the 999del5 mutation in Icelandic breast and ovarian cancer patients G Johannesdottir, J Gudmundsson, JT Bergthorsson, A Arason, ... Cancer research 56 (16), 3663-3665, 1996 | 321 | 1996 |
| Identification of six new susceptibility loci for invasive epithelial ovarian cancer KB Kuchenbaecker, SJ Ramus, J Tyrer, A Lee, HC Shen, J Beesley, ... Nature genetics 47 (2), 164-171, 2015 | 320 | 2015 |
| Targeted prostate cancer screening in BRCA1 and BRCA2 mutation carriers: results from the initial screening round of the IMPACT study EK Bancroft, EC Page, E Castro, H Lilja, A Vickers, D Sjoberg, M Assel, ... European urology 66 (3), 489-499, 2014 | 307 | 2014 |
| Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer CE Geyer Jr, JE Garber, RD Gelber, G Yothers, M Taboada, L Ross, ... Annals of oncology 33 (12), 1250-1268, 2022 | 259 | 2022 |
| Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics G Jönsson, J Staaf, J Vallon-Christersson, M Ringnér, K Holm, C Hegardt, ... Breast Cancer Research 12, 1-14, 2010 | 253 | 2010 |
| Interim results from the IMPACT study: evidence for prostate-specific antigen screening in BRCA2 mutation carriers EC Page, EK Bancroft, MN Brook, M Assel, MH Al Battat, S Thomas, ... European urology 76 (6), 831-842, 2019 | 241 | 2019 |
| Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome J Staaf, M Ringnér, J Vallon-Christersson, G Jönsson, PO Bendahl, ... Journal of Clinical Oncology 28 (11), 1813-1820, 2010 | 229 | 2010 |
